Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:33:45.943Z.
Calculation as of: 2026-10-06T15:33:45.943Z.
Quote observation: 2026-10-06T15:31:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 53f0b653117dfddf80d57e74ba570551200adc0db5709ea8e1a3c029d43ac92d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
MBX Biosciences, Inc. Common Stock
Market Cap
$2.75B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.70B
EBITDA Yield
10.50%
TTM Avg
12.59%
3Y Avg
12.00%
5Y Avg
11.83%
Market Cap
$2.69B
EBITDA Yield
7.55%
TTM Avg
8.87%
3Y Avg
7.02%
5Y Avg
6.94%
Market Cap
$2.82B
EBITDA Yield
3.67%
TTM Avg
2.99%
3Y Avg
2.18%
5Y Avg
2.18%
Market Cap
$2.64B
EBITDA Yield
N/A
TTM Avg
27.22%
3Y Avg
27.22%
5Y Avg
27.22%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $2.75B | N/A | N/A | N/A | N/A |
| Precigen, Inc. (PGEN)vs › | $2.73B | N/A | N/A | N/A | N/A |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | 10.50% | 12.59% | 12.00% | 11.83% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 7.55% | 8.87% | 7.02% | 6.94% |
| Neogen Corporation (NEOG)vs › | $2.69B | 3.04% | 3.86% | 4.98% | 4.09% |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 1.29% | 1.25% | 1.25% | 1.25% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.63B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 3.67% | 2.99% | 2.18% | 2.18% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.64B | N/A | 27.22% | 27.22% | 27.22% |
| Privia Health Group, Inc. (PRVA)vs › | $2.59B | N/A | 1.49% | 1.19% | 1.11% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
